Teachers Retirement System of The State of Kentucky Sells 1,879 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Teachers Retirement System of The State of Kentucky reduced its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,644 shares of the medical research company's stock after selling 1,879 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.10% of Bio-Rad Laboratories worth $8,753,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. MML Investors Services LLC increased its holdings in Bio-Rad Laboratories by 98.8% in the fourth quarter. MML Investors Services LLC now owns 10,660 shares of the medical research company's stock worth $3,502,000 after purchasing an additional 5,299 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Bio-Rad Laboratories by 9.6% in the fourth quarter. MetLife Investment Management LLC now owns 10,848 shares of the medical research company's stock worth $3,564,000 after purchasing an additional 948 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Bio-Rad Laboratories in the fourth quarter worth approximately $539,000. Dimensional Fund Advisors LP increased its holdings in Bio-Rad Laboratories by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company's stock worth $245,106,000 after purchasing an additional 91,690 shares in the last quarter. Finally, GeoWealth Management LLC increased its holdings in Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BIO has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Finally, StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $380.20.

Bio-Rad Laboratories Stock Down 3.0 %

Shares of NYSE:BIO traded down $7.52 during mid-day trading on Friday, hitting $242.22. 377,689 shares of the company traded hands, compared to its average volume of 317,205. The stock has a market cap of $6.78 billion, a P/E ratio of -3.72 and a beta of 1.12. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $215.38 and a 12-month high of $387.99. The stock has a 50-day moving average price of $251.03 and a two-hundred day moving average price of $308.11.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.